Abstract
Background: Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus. The majority are malignant. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization. Objective: To review and discuss new treatments for patients with metastatic NETs. Method: Review of the published literature during the last 5 years on treatment of patients with NETs. Results/conclusion: Several new drugs with various mechanisms of action including cytotoxic drugs, tyrosine kinase receptor inhibitors and antiangiogenic drugs as well as radiolabelled substances have been introduced during recent years. Many of these compounds have shown promising results in patients with NETs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
